By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
Filings Reveal Bristol-Myers Squibb (BMY) Passes on Option to Buy f-Star 4/28/2017 6:39:41 AM
Why Bristol-Myers Squibb (BMY) Just Became an Even More Attractive Takeover Target 4/28/2017 6:30:55 AM
A Refreshing Voice At Bristol-Myers Squibb (BMY) 4/28/2017 6:24:32 AM
Bristol-Myers Squibb (BMY) Release: China FDA Approves Country‚Äôs First All-Oral Regimen For Chronic Hepatitis C, Daklinza (Daclatasvir) In Combination With Sunvepra (Asunaprevir) 4/28/2017 6:18:52 AM
Bristol-Myers Squibb (BMY) Reports First Quarter Financial Results 4/27/2017 5:37:12 AM
Exec Who Orchestrated Promedior's $1.25 Billion Buyout Deal From Bristol-Myers Squibb (BMY) To Helm Proclara 4/26/2017 8:09:10 AM
TRANSGENE (ENX:TNG) And Bristol-Myers Squibb (BMY) Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer 4/25/2017 6:59:46 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval Of Opdivo (Nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer 4/24/2017 7:47:48 AM
Bristol-Myers Squibb (BMY)'s NASH Candidate Hits Main Goals In Mid-Stage Study 4/24/2017 7:25:34 AM
Bristol-Myers Squibb (BMY) And Nordic Bioscience A/S Announce Collaboration For Fibrosis Biomarker Technology 4/17/2017 9:05:01 AM
12345678910...
//-->